Skip to content

US · XRTX · BIOTECHNOLOGY

XORTX Therapeutics Inc. (XRTX) intrinsic value and stock valuation

$0.84as of 2026-11-21 · Mkt cap 609.89K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

XORTX Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values XRTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from XRTX’s statements →

XORTX Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Calgary, AB T2L 2M1 xortx.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$0.00
20142025
Net income
-$-2.66M
20142025
Free cash flow
-$-2.82M
20152025
Total equity
$2.08M+10.5% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-3.31M-$-3.92M-$-6.16M-$-12.43M-$-2.9M
Net income-$-2.66M-$-3.15M-$-2.86M-$-6.99M-$-1.65M
EPSd-$-14M-$-26.25M-$-35.75M-$-116.5M-$-41.25M
Operating cash flow-$-2.82M-$-3.5M-$-6.58M-$-8.96M-$-4.8M
Capital expenditure$0.00-$-40K-$-50K-$-50K-$-30K
Free cash flow-$-2.82M-$-3.5M-$-6.63M-$-9.01M-$-4.83M
Total assets$2.68M$4.09M$5.47M$12.4M$17.4M
Total debt$40K$40K$10K$80K$0.00
Net debt-$-830K-$-2.43M-$-3.44M-$-10.36M-$-14.87M
Total equity$2.08M$3.33M$4.64M$7M$13.2M
Cash and short-term investments$860K$2.47M$3.45M$10.4M$14.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$110K$110K$140K$70K$20K
Gross profit-$-110K-$-110K-$-140K-$-70K-$-20K
Research and development expenses$570K$180K$2.41M$9.16M$850K
Selling, general and administrative expenses$1.83M$3.63M$2.39M$3.28M$2.05M
Other expenses$790K$1.65M$1.4M$1.13M$0.00
Operating expenses$3.2M$3.81M$4.81M$12.4M$2.9M
Cost and expenses$3.31M$3.92M$6.16M$12.4M$2.9M
Interest income$40K$120K$250K$140K$0.00
Interest expense$0.00$0.00$0.00$0.00$10K
Depreciation and amortization$110K$110K$140K$80K$20K
Ebitda-$-3.14M-$-3.04M-$-6.01M-$-9.41M-$-2.9M
Operating income-$-3.31M-$-3.92M-$-6.16M-$-12.43M-$-2.9M
Total other income/expenses, net$610K$770K$3.96M$1.98M$1.25M
Income before tax-$-2.7M-$-3.15M-$-2.2M-$-9.49M-$-1.65M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-2.66M-$-3.15M-$-2.86M-$-6.99M-$-1.65M
Weighted average shares outstanding$190K$120K$80K$60K$40K
Weighted average diluted shares outstanding$190K$120K$80K$60K$40K
Balance sheet
20252024202320222021
Cash and short-term investments$860K$2.47M$3.45M$10.4M$14.9M
Net receivables$80K$20K$60K$80K$40K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$970K$2.68M$4.07M$10.9M$15.9M
Property, plant and equipment, net$40K$30K$20K$90K$0.00
Goodwill and intangible assets$190K$180K$180K$200K$200K
Long-term investments$1.2M$1.2M$0.00$0.00$1.61M
Total non-current assets$1.71M$1.42M$1.4M$1.48M$1.47M
Total assets$2.68M$4.09M$5.47M$12.4M$17.4M
Accounts payable$400K$60K$200K$1.29M$320K
Short-term debt$40K$40K$10K$70K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$600K$760K$290K$1.51M$550K
Long-term debt$0.00$0.00$0.00$10K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$530K$3.87M$3.63M
Capital lease obligations$0.00$0.00$10K$80K$0.00
Total liabilities$600K$760K$830K$5.38M$4.18M
Common stock$20.2M$18.5M$17.1M$16.5M$16.1M
Retained earnings-$-23.78M-$-21.16M-$-23.54M-$-15.7M-$-7.98M
Accumulated other comprehensive income (loss)$5.72M$6.01M$5.4M$8.04M$6.44M
Total equity$2.08M$3.33M$4.64M$7M$13.2M
Total investments$1.2M$1.2M$0.00$0.00$1.61M
Total debt$40K$40K$10K$80K$0.00
Net debt-$-830K-$-2.43M-$-3.44M-$-10.36M-$-14.87M
Cash flow statement
20252024202320222021
Net income-$-2.7M-$-3.15M-$-2.16M-$-7.72M-$-1.58M
Depreciation and amortization$110K$110K$110K$60K$10K
Stock-based compensation$30K$120K$120K$490K$580K
Change in working capital$340K$110K-$-1.03M$790K-$-1.08M
Accounts receivable-$-60K$40K$0.00-$-40K-$-30K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-2.82M-$-3.68M-$-6.58M-$-8.17M-$-4.8M
Investments in property, plant and equipment-$-60K-$-40K-$0.00-$-40K-$-30K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-300K-$-40K-$-50K-$-50K-$-30K
Common stock issued$1.54M$2.71M$0.00$5M$18.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.45M$2.78M-$-360K$3.91M$19.4M
Net change in cash-$-1.73M-$-970K-$-6.99M-$-4.44M$14.7M
Cash at end of period$860K$1.72M$3.45M$10.4M$14.9M
Operating cash flow-$-2.82M-$-3.5M-$-6.58M-$-8.96M-$-4.8M
Capital expenditure$0.00-$-40K-$-50K-$-50K-$-30K
Free cash flow-$-2.82M-$-3.5M-$-6.63M-$-9.01M-$-4.83M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About XORTX Therapeutics Inc.

        XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.

        CEO
        Allen Warren Davidoff
        Employees
        2
        Beta
        0.08

        Explore

        Frequently asked questions

        What is the intrinsic value of XORTX Therapeutics Inc. (XRTX)?

        InvestorsCraft does not currently publish an intrinsic value for XRTX. How the IC value is calculated.

        Is XRTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for XRTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.